Investigating how STING signaling in T cells affects gut health and inflammatory bowel diseases
Official title: STING signaling in T cells regulation of intestinal homeostasis and inflammatorybowel diseases
Funded at Northwestern University at Chicago · NIH-11017252 · Data updated 2026-11-12
This study is looking at how a molecule called STING helps control immune responses in the gut, which could lead to better treatments for conditions like colitis and other inflammatory bowel diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $489,898 |
| NIH project number | 7R01DK124132-05 |
| Project ID | NIH-11017252 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from inflammatory bowel diseases such as ulcerative colitis or Crohn's disease.
✕Less likely to help
Patients with non-inflammatory gastrointestinal disorders or those without any bowel-related issues may not benefit from this research.
What this research studies
This research explores the role of STING, a key molecule in the immune system, in regulating T cell responses that influence intestinal health. By studying how STING signaling affects the production of important immune factors, the research aims to understand its impact on conditions like colitis and other inflammatory bowel diseases. The approach involves using specialized mouse models to observe changes in immune responses and inflammation in the gut. Patients may benefit from insights that could lead to new treatments for gut-related inflammatory conditions.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing inflammatory bowel diseases and improving gut health.
How similar studies have gone: Previous research has shown promising results in targeting STING signaling for therapeutic purposes, indicating potential for success in this area.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Cong, Yingzi — Northwestern University at Chicago
- Study coordinator: Cong, Yingzi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.